Panacea Biotec has secured a $20 million long-term loan from the US International Development Finance Corporation to expand its hexavalent vaccine production. This funding will help the company meet global demand for childhood immunization, supplying vaccines to UN agencies. The hexavalent vaccine, EasySix, protects against six diseases and is expected to see significant demand growth by 2030.
News
Panacea Biotec gets $20 million loan from US government for hexavalent vaccine capacity expansion
October 21, 2024Panacea Biotec has secured a $20 million long-term loan from the US International Development Finance Corporation to expand its hexavalent vaccine production. This funding will help the company meet global demand for childhood immunization, supplying vaccines to UN agencies. The hexavalent vaccine, EasySix, protects against six diseases and is expected to see significant demand growth by 2030.